Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 24.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,021 shares of the company’s stock after selling 1,611 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Prestige Consumer Healthcare were worth $392,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $84,932,000. Raymond James Financial Inc. acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $42,593,000. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $40,009,000. Bessemer Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after purchasing an additional 292,144 shares during the last quarter. Finally, Boston Trust Walden Corp boosted its holdings in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after purchasing an additional 252,089 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

PBH has been the topic of several analyst reports. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Friday, May 9th. Oppenheimer increased their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Canaccord Genuity Group increased their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Finally, DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $93.33.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.3%

NYSE:PBH opened at $85.83 on Thursday. The business’s 50-day moving average is $83.16 and its two-hundred day moving average is $81.62. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare Inc. has a 12 month low of $62.35 and a 12 month high of $90.04. The firm has a market capitalization of $4.25 billion, a PE ratio of 20.10, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the company posted $1.02 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.